S Gillessen1, T Powles2, L Lim2, P Wilson2, J Shamash3. 1. Department of Medical Oncology, Experimental Cancer Medicine Centre, St Bartholomew's Hospital, West Smithfield, London, UK; Department of Oncology-Haematology, Kantonsspital St Gallen, Switzerland. 2. Department of Medical Oncology, Experimental Cancer Medicine Centre, St Bartholomew's Hospital, West Smithfield, London, UK. 3. Department of Medical Oncology, Experimental Cancer Medicine Centre, St Bartholomew's Hospital, West Smithfield, London, UK. Electronic address: jonathan.shamash@bartsandthelondon.nhs.uk.
Abstract
BACKGROUND: In some institutions advanced metastatic germ-cell tumour (GCT) is treated with low-dose induction chemotherapy in specific settings. There is a lack of published data supporting its use. The data presented here specifically address this issue for the first time. PATIENTS AND METHODS: Twenty patients with metastatic GCT treated were with low-dose induction chemotherapy [Baby-BOP (bBOP)] between 1998 and 2009. We report the toxicity and outcome and compare it with a control group. RESULTS: bBOP was well tolerated with no treatment-related deaths and a lack of chemotherapy-related toxicity. It was associated with a significant fall in tumour markers (median HCG fell from 35 195 to 11 028 IU/l). The first subsequent cycle of standard chemotherapy was administered a median of 9.5 days after initial treatment and was not associated with excess toxicity. The 2-year overall survival of the poor-prognosis patients treated with bBOP was 79.0% [95% confidence interval (CI) 48% to 93%], which is not significantly different from the 2-year overall survival of 80% [95% CI 55% to 92%] of the poor-prognosis patients, who did not receive bBOP. CONCLUSION: Low-dose induction chemotherapy can be given safely in selected individuals and does not adversely affect subsequent chemotherapy or outcome.
BACKGROUND: In some institutions advanced metastatic germ-cell tumour (GCT) is treated with low-dose induction chemotherapy in specific settings. There is a lack of published data supporting its use. The data presented here specifically address this issue for the first time. PATIENTS AND METHODS: Twenty patients with metastatic GCT treated were with low-dose induction chemotherapy [Baby-BOP (bBOP)] between 1998 and 2009. We report the toxicity and outcome and compare it with a control group. RESULTS:bBOP was well tolerated with no treatment-related deaths and a lack of chemotherapy-related toxicity. It was associated with a significant fall in tumour markers (median HCG fell from 35 195 to 11 028 IU/l). The first subsequent cycle of standard chemotherapy was administered a median of 9.5 days after initial treatment and was not associated with excess toxicity. The 2-year overall survival of the poor-prognosis patients treated with bBOP was 79.0% [95% confidence interval (CI) 48% to 93%], which is not significantly different from the 2-year overall survival of 80% [95% CI 55% to 92%] of the poor-prognosis patients, who did not receive bBOP. CONCLUSION: Low-dose induction chemotherapy can be given safely in selected individuals and does not adversely affect subsequent chemotherapy or outcome.
Authors: Katarina Rejlekova; Katarina Kalavska; Marek Makovnik; Nikola Hapakova; Michal Chovanec; Valentina De Angelis; Jana Obertova; Patrik Palacka; Zuzana Sycova-Mila; Jozef Mardiak; Michal Mego Journal: Front Oncol Date: 2022-06-17 Impact factor: 5.738